Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD123 CAR-T cells

A preparation of autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD123 CAR-T cells target and bind to CD123 expressed on the surface of tumor cells. This induces selective toxicity in CD123-expressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. It is overexpressed on a variety of cancers, including myeloid leukemia, and the increased expression of CD123 on leukemic stem cells (LSCs) is associated with poor prognosis.
Synonym:autologous anti-CD123 CAR T cells
autologous anti-CD123 chimeric antigen receptor T cells
CD123 CAR-T cells
Search NCI's Drug Dictionary